Results 101 to 110 of about 73,942 (286)

A consensus roadmap for post‐traumatic epilepsy: Clinical biomarkers, research priorities, policy barriers, and pathways to interventional trials

Epilepsia, EarlyView.
Abstract Understanding the mechanisms underlying post‐traumatic epilepsy (PTE) following traumatic brain injury (TBI), and developing strategies to prevent or modify its progression, has been the focus of large collaborative efforts within the epilepsy and TBI research communities for over a decade.
Elisa R. Zanier, Ilaria Lisi, Elaine K. O'Loughlin, Federico Moro, Edilberto Amorim, David L. Brody, Daniel J. Correa, Dominique Duncan, Pavel Klein, Firas H. Kobeissy, Wolfgang Löscher, Edward J. Needham, Asla Pitkänen, Mary Jo Pugh, Jack Somers, Annamaria Vezzani, Amy K. Wagner, Laura S. Lubbers, International Conference on PTE Attendees, Denes Agoston, Edilberto Amorim, Sneha Anand, Hibah Awwad, Ginevra Bayon, Naima Belhachemi, Akash Bera, Costanza Bertani, Guido Bertolini, David L. Brody, Serena Brusatori, Francesca Buffelli, Aurora Chiapperini, Mara Chioccola, Severn Churn, Daniel J. Correa, Ramon Diaz‐Arrastia, Chris Dulla, Dominique Duncan, Chiara Ferlito, Aristea Galanopoulou, Angela Galic, Heidi Matos Galicia, Bin Gu, William Haskins, Victoria Johnson, Nigel Jones, Lowie Joseph, Pavel Klein, Firas Kobaissy, Ilaria Lisi, David Loane, Luther Loose, Laura S. Lubbers, Wolfgang Löscher, Edoardo Mazzone, Melissa Miller, Federico Moro, Edward J. Needham, Irma Wati Ngadimon, Terence O’Brien, Elaine K. O’Loughlin, Asla Pitkanen, Mary Jo Pugh, Teresa Giovanna Ravizza, Giuseppe Remuzzi, Massimo Rizzi, Rossella Di Sapia, Tawfeeq Shekh‐Ahmad, Doug Smith, Jack Somers, Kevin Staley, Francesca Tribuzio, Alexandra Ulyanova, Gloria Vegliante, Annamaria Vezzani, Joost Wagenaar, Amy K. Wagner, Kevin W. Wang, Justin Weppner, Peter J. West, Karen Wilcox, John Wolf, Elisa R. Zanier   +82 more
wiley   +1 more source

Successful treatment of recalcitrant follicular lichen planus (lichen planopilaris) with the topical JAK 1/2 inhibitor ruxolitinib

JEADV Clinical Practice
We report the successful treatment of a patient with refractory follicular lichen planus (LP) with topical ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, which resulted in significant improvement of lesional skin within 1 month of daily use.
Tanja Fetter, Dagmar Wilsmann‐Theis, Luka deVos‐Hillebrand, Natalija Novak, Joerg Wenzel   +4 more
doaj   +1 more source

Strategies for Identification and Mitigation of Sanguinarine in Mustard Oil Adulterated by Argemone—A Comprehensive Review

Food Chemistry International, EarlyView.
Sanguinarine, a toxic alkaloid present in argemone, can lead to epidemic dropsy or chronic diseases through DNA intercalation and immune system suppression. Regulatory efforts face challenges due to economic motivations for adulteration as well as technical, social, and infrastructure barriers.
Gururaj Pejavara Narayana, Subhangi Panigrahi, Suresh Kumar Kalakandan, Hema Vincent, Ashish Rawson   +4 more
wiley   +1 more source

Beyond Gut Modulation: A Critical Review of the Therapeutic Potential, Safety, and Clinical Prospects of Natural Polysaccharides for IBD

Food Safety and Health, EarlyView.
In this review, we critically summarized the application of natural polysaccharides (NPs) for the treatment of IBD. This approach combines, in a unique way (right), the basic structure–activity relationships of NPs from different origins (left) with their multipronged mode of action, which involves modulation of the gut microbiota and other ...
Felix Danso, A. M. Abd El‐Aty, Kwaku Amoah, Xianghong Ju   +3 more
wiley   +1 more source

Janus kinase 1/2 inhibition for the treatment of autoinflammation associated with heterozygous TNFAIP3 mutation [PDF]

, 2019
We report a case of autoinflammation caused by a heterozygous variant in TNFAIP3 manifesting as progressive neuroinflammation. Mutant A20 protein failed to control interferon-dependent transcription. We demonstrate excellent therapeutic response to Janus
Mulhern, CM, Hemingway, C, Eleftheriou, D, Jacques, T, Hong, Y, D'Arco, F, Omoyinmi, E, Brogan, PA   +7 more
core  

online supplementary file 1 - Supplemental material for The Rate of Infections With Janus Kinase Inhibitor Treatment for Atopic Dermatitis: A Systematic Review and Meta-Analysis

, 2023
Supplemental material, online supplementary file 1, for The Rate of Infections With Janus Kinase Inhibitor Treatment for Atopic Dermatitis: A Systematic Review and Meta-Analysis by Nawar Tarafdar, Muskaan Sachdeva, Natnaiel M.
Natnaiel M. Dubale (17408653), Jorge R. Georgakopoulos (12281207), Ciaran Smythe (17408656), Yuliya Lytvyn (4543561), Asfandyar Mufti (9700375), Khalad Maliyar (9700378), Jensen Yeung (5170499), Nawar Tarafdar (17374646), Muskaan Sachdeva (9447619)   +8 more
core   +1 more source

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor

Journal of Experimental Pharmacology, 2016
Jack W Singer,1 Suliman Al-Fayoumi,1 Haiching Ma,2 Rami S Komrokji,3 Ruben Mesa,4 Srdan Verstovsek5 1Translational Medicine, CTI BioPharma Corp., Seattle, WA, 2Department of Research and Development, Reaction Biology, Malvern, PA, 3Department of ...
Singer J, Al-Fayoumi S, Ma H, Komrokji R, Mesa R, Verstovsek S   +5 more
doaj  

The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review

Dermatology and Therapy
Alopecia areata is an inflammatory autoimmune disease that presents as non-scarring hair loss in adults and children and causes substantial psychological distress, economic burden, and reduced quality of life for those affected.
Hussein Abdel Dayem, Anwar Al Hammadi, Ashraf Reda, Fatima Albreiki, Ayman Al Naeem, Ahmed Ameen, Mohamed Ahmed, Huda Rajab Ali, Mohamed Elrayes, Gozde Senay, Muna Al Murrawi   +10 more
doaj   +1 more source

Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis

Life
Abrocitinib, an oral small-molecule Janus Kinase 1 (JAK1) inhibitor, is primarily approved for treating moderate-to-severe atopic dermatitis (AD) in adults and adolescents aged 12 and older. This review examines the emerging off-label uses of Abrocitinib.
George G. Mitroi, George F. Mitroi, Oana Maria Ică, Florin Anghelina, Mircea Sorin Ciolofan, Mihaela Roxana Mitroi   +5 more
doaj   +1 more source

Characterizing the role of p21-Activated Kinase 3 (PAK3) in AP-1-induced transformation

, 2014
Includes bibliographical references.Previous studies identified p21-Activated Kinase 3 (PAK3), a serine/threonine kinase, as a potential AP-1 target gene.
Holderness-Parker, Nina Alison Victoria
core